Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

AstraZeneca Iressa NDA Review Complicated By Pneumonia Reports

Executive Summary

The final FDA review of AstraZeneca's Iressa NDA is being complicated by reports of interstitial pneumonia possibly associated with use of the non-small cell lung cancer agent
Advertisement

Related Content

Iressa Clears FDA: Phase IV Symptom Trial Will Be First Shot At Full Approval
Iressa Clears FDA: Phase IV Symptom Trial Will Be First Shot At Full Approval
Iressa Postmarketing Trial Modeled On Tarceva Phase III Under Consideration
Iressa Postmarketing Trial Modeled On Tarceva Phase III Under Consideration
Iressa User Fee Date Pushed To May; Will Advisory Cmte. Take Second Look?
Iressa User Fee Date Pushed To May; Will Advisory Cmte. Take Second Look?
Iressa Activity Not Likely Predicted By EGFR Expression Level – AstraZeneca
Iressa Cross-Over Study Could Show Clinical Benefit, AZ Says; ODAC Is Wary
Iressa Cross-Over Study Could Show Clinical Benefit, AZ Says; ODAC Is Wary
AstraZeneca Iressa Focus Is Sequential Therapy After INTACT Studies Fail
Advertisement
UsernamePublicRestriction

Register

PS040711

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel